Vandetanib (Van)
Vandetanib is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. Vandetanib is well absorbed from the gut, reaches peak blood plasma concentrations 4 to 10 hours after application, and has a half-life of 19 days on average. It has to be taken for about three months to achieve a steady-state concentration. In the blood, it is almost completely (90–96%) bound to plasma proteins such as albumin. It is metabolised to N-desmethylvandetanib via CYP3A4 and to vandetanib-N-oxide via FMO1 and 3. Both of these are active metabolites. Vandetanib is excreted via the faeces (44%) and the urine (25%) in form of the unchanged drug and the metabolites.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Vandetanib (Van) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Vandetanib (Van) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Vandetanib (Van) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Vandetanib (Van) CLIA Kit Customized Service Offer
n/a ELISA Kit for Vandetanib (Van) ELISA Kit Customized Service Offer